Hepcidin Peptide Analogues for Ferroportin Binding and Iron Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for iron overload diseases such as hereditary hemochromatosis and iron-loading anemias are burdensome and ineffective, and hepcidin, a peptide hormone regulating iron homeostasis, faces challenges in synthesis due to aggregation and precipitation, limiting its use as a drug.
Innovation Solution
Development of novel hepcidin peptide analogues and dimers with improved solubility, stability, and potency, which can be synthesized affordably and effectively bind to ferroportin to regulate iron levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hepcidin is used as a drug to treat iron overload diseases, then iron homeostasis regulation is improved, but synthesis difficulty increases due to aggregation and precipitation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of hepcidin through amino acid substitutions, deletions, or modifications. These structural parameter changes improve solubility and reduce aggregation/precipitation during synthesis, while maintaining the peptide's ability to bind ferroportin and regulate iron homeostasis effectively.
Solution Approach 2:
The patent creates composite peptide structures by combining hepcidin sequences with other amino acid sequences or modifying existing sequences to form chimeric peptides. These composite structures improve manufacturability by reducing aggregation while preserving the iron-regulatory function through maintained ferroportin binding capability.
2Reliability
If hepcidin is used to treat iron overload diseases, then iron levels are reduced, but treatment burden increases due to frequent administration and side effects
Solution Approach 1:
The patent employs dynamics by engineering hepcidin analogues with optimized pharmacokinetic properties, including extended half-life and improved stability. These dynamic modifications allow for less frequent administration intervals while maintaining effective iron level control, thereby reducing treatment burden on patients.
Solution Approach 2:
The patent modifies physical and chemical parameters of hepcidin to improve its pharmacokinetic profile. Changes in molecular weight, charge distribution, and structural stability result in reduced clearance rates and extended circulation time, enabling less frequent dosing and reduced treatment burden while maintaining therapeutic efficacy.
3Quantity of substance
If current iron chelation treatment is used for iron overload, then iron removal is achieved, but side effects and ineffectiveness increase
Solution Approach 1:
The patent uses hepcidin and its analogues as intermediary molecules that naturally bind to ferroportin to regulate iron homeostasis. This physiological mechanism provides selective iron removal from macrophages and enterocytes without the non-specific toxicity and severe side effects associated with conventional iron chelation agents, achieving iron removal with improved safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide analogues and dimers provide a viable alternative to hepcidin, effectively reducing serum iron levels and treating iron overload diseases with fewer side effects and improved efficacy compared to existing treatments.
Implementation Method 1
Hepcidin acts by binding to its receptor, the iron export channel ferroportin, causing its internalization and degradation
Data Source
AI summary
The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.